To explore the clinical study of tislelizumab combined with nab-paclitaxel and cisplatin(Nab-PP) for advanced lung squamous cell carcinoma with high expression of programmed death-ligand(PD-L)1.
The clinical data of patients with advanced lung squamous cell carcinoma with high PD-L1 expression who were admitted to our hospital from November 2020 to June 2023 were retrospectively collected. A total of 99 patients who received Nab-PP combined with tislelizumab treatment(the monoclonal antibody group), and 91 patients who received only Nab-PP treatment during the same period(the reference group) were initially included. The propensity score matching method was adopted, and the matching was carried out according to the 1∶1 ratio principle. Eventually, 52 patients in each group were successfully matched. The clinical efficacy, immune indicators, tumor markers, degree of primary lesion remission, functional status, quality of life scores, survival situation and safety between the two groups were compared.
The objective response rate of the monoclonal antibody group(55.77%) was higher than that of the reference group(32.69%, P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ and natural killer cells in the monoclonal antibody group were all higher than those in the reference group, while the levels of squamous cell carcinoma antigen, carcinoembryonic antigen, cytokeratin 19 fragment and matrix metalloproteinase 9 were all lower than those in the reference group(P<0.05). In the monoclonal antibody group, there were 18 cases in stage Ⅲb. Among them, 16 cases(88.9%) eventually underwent radical surgery. Postoperative pathology confirmed 9 cases(56.3%) of major pathological response and 7 cases(43.8%) of pathological complete response. After the treatment, the Karnofsky performance status and the systematic evaluation of pulmonary function - lung score of the monoclonal antibody group were both higher than those of the reference group(P<0.05). The median progression-free survival and overall survival in the monoclonal antibody group were significantly higher than those in the reference group(χ2=13.882, 12.323, P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).
Tislelizumab combined with the Nab-PP regimen can significantly improve the clinical efficacy of patients with advanced lung squamous cell carcinoma with high PD-L1 expression, prolong survival time, and has a good safety profile. It is suitable for clinical promotion and application.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |